Relapsed small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Clinical trials, cohort studies or retrospective observational studies evaluating the efficacy and/or safety of nab-paclitaxel or paclitaxel in patients with SCLC. (2) Studies evaluate patients with relapsed SCLC (second-line treatment or later). (3) Full-text papers
Exclusion criteria
Exclusion criteria: (1) Systematic review or meta-analysis papers. (2) Case series with less than 5 patients (3) Patients who used the regimen of carboplatin, nab-paclitaxel, or carboplatin, paclitaxel. (4) Clinical studies which do not evaluate neither the efficacy nor the safety of nab-paclitaxel or paclitaxel. (5) Papers not written in English. (6) Conference abstracts
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is to evaluate the efficacy and the safety of nab-paclitaxel or paclitaxel monotherapy as 2nd line or later treatment for extensive stage SCLC. 3-month progression survival rate, 6-month overall survival rate, objective response rate and disease control rate will be evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| As the additional analysis, the frequency of adverse events of nab-paclitaxel or paclitaxel such as the occurrence rate of neuropathy, drug-induced pneumonia, neutropenia, anemia, thrombocytopenia and any G5 adverse events. | — |
Countries
Japan
Contacts
Public ContactSousuke Kubo
Yokohama City University Graduate School of Medicine Department of Pulmonology
Outcome results
None listed